Please use this identifier to cite or link to this item:
https://dipositint.ub.edu/dspace/handle/2445/52827
Title: | MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin Lymphoma patients |
Author: | Navarro Ponz, Alfons Muñoz, Carmen Gaya, Anna Díaz Beyà, Marina Gel, Bernat Tejero Villalba, Rut Díaz Sánchez, Tania Martínez Pozo, Antonio Monzó Planella, Mariano |
Keywords: | Malaltia de Hodgkin Micro RNAs Limfomes Hodgkin's disease MicroRNAs Lymphomas |
Issue Date: | 21-May-2013 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | Background: In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways. Design and Methods: We analyzed eight miR-SNPs by allelic discrimination in 141 patients with Hodgkin lymphoma and correlated the results with treatment-related toxicity, response, disease-free survival (DFS) and overall survival (OS). Results: The KRT81 (rs3660) GG genotype was associated with an increased risk of neurological toxicity (P=0.016), while patients with XPO5 (rs11077) AA or CC genotypes had a higher rate of bleomycin-associated pulmonary toxicity (P=0.048). Both miR-SNPs emerged as independent factors in the multivariate analysis. The XPO5 AA and CC genotypes were also associated with a lower response rate (P=0.036). XPO5 (P=0.039) and TRBP (rs784567) (P=0.022) genotypes emerged as prognostic markers for DFS, and XPO5 was also associated with OS (P=0.033). In the multivariate analysis, only XPO5 emerged as an independent prognostic factor for DFS (HR: 2.622; 95%CI 1.039-6.620; P=0.041). Given the influence of XPO5 and TRBP as individual markers, we then investigated the combined effect of these miR-SNPs. Patients with both the XPO5 AA/CC and TRBP TT/TC genotypes had the shortest DFS (P=0.008) and OS (P=0.008). Conclusion: miR-SNPs can add useful prognostic information on treatment-related toxicity and clinical outcome in Hodgkin lymphoma and can be used to identify patients likely to be chemoresistant or to relapse. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0064716 |
It is part of: | PLoS One, 2013, vol. 8, num. 5, p. e64716 |
URI: | http://hdl.handle.net/2445/52827 |
Related resource: | http://dx.doi.org/10.1371/journal.pone.0064716 |
ISSN: | 1932-6203 |
Appears in Collections: | Articles publicats en revistes (Fonaments Clínics) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
624379.pdf | 332.13 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License